COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
Budesonide study #1 of 3
2/8 Early treatment study
Ramakrishnan et al., Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00160-0 (preprint 2/8) (Peer Reviewed)
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
Source   PDF   Share   Tweet
RCT with 73 budesonide patients and 73 control patients, showing significantly lower combined risk of an ER visit or hospitalization, and lower risk of no recovery at day 14.

Ramakrishnan et al., 2/8/2021, Randomized Controlled Trial, United Kingdom, Europe, peer-reviewed, 24 authors.
risk of hospitalization/ER, 81.8% lower, RR 0.18, p = 0.02, treatment 2 of 73 (2.7%), control 11 of 73 (15.1%), ITT.
risk of hospitalization/ER, 90.1% lower, RR 0.10, p = 0.004, treatment 1 of 70 (1.4%), control 10 of 69 (14.5%), PP.
risk of no recovery, 67.1% lower, RR 0.33, p = 0.003, treatment 7 of 70 (10.0%), control 21 of 69 (30.4%), PP, day 14.
recovery time, 12.5% lower, relative time 0.88, treatment 70, control 69, PP.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 3 studies
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary; multiple approaches are required to protect all people from all existing and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop to submit images